Rangwala Reshma 4
4 · Karyopharm Therapeutics Inc. · Filed May 2, 2022
Insider Transaction Report
Form 4
Rangwala Reshma
EVP & Chief Medical Officer
Transactions
- Award
Common Stock
2022-04-29+65,000→ 65,000 total - Award
Stock Option (right to buy)
2022-04-29+100,000→ 100,000 totalExercise: $6.10Exp: 2032-04-28→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Inducement Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning April 29, 2023.
- [F2]This option was granted on April 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on April 29, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.